Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Promising Pipeline | Explore Nurix's innovative protein degradation platform and its lead candidate bexobrutideg, showing encouraging results in CLL and NHL clinical trials |
Financial Health | Despite operating losses, Nurix maintains a strong cash position of $609.6 million, funding operations into 2027 with analyst targets ranging from $16 to $41 |
Strategic Expansion | Delve into Nurix's move beyond oncology into autoimmune diseases, potentially broadening its market reach and diversifying revenue streams |
Competitive Landscape | Learn about Nurix's partnerships with major pharmaceutical companies and how it navigates intense competition in the rapidly evolving biotechnology secto |
Metrics to compare | NRIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRIXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.6x | −1.1x | −0.5x | |
PEG Ratio | −0.35 | −0.06 | 0.00 | |
Price/Book | 1.6x | 2.2x | 2.6x | |
Price / LTM Sales | 8.3x | 9.2x | 3.3x | |
Upside (Analyst Target) | 197.9% | 326.4% | 43.4% | |
Fair Value Upside | Unlock | 7.2% | 7.1% | Unlock |